BDR Pharmaceuticals has launched its first generic – Apalutamide for the treatment of prostate cancer in India.
The brand claims that Apalutamide is significant when it comes to improving overall survival as well as radiographic progression-free survival.
Over the last 15 years, BDR Group of companies has grown steadily and have become a household name in the pharmaceutical Industry. The brand has earned name recognition in both domestic and international arenas. The group focuses on development in four specialized therapeutic segments – Oncology, Critical Care, Gynecology, and Neurology.
BDR Pharmaceutical Generic
The medicine Apatide (Apalutamide) will be made available in India. You will find it in strength of 60 mg and in packs of 60 tablets and 120 tablets.
It is priced –
- 60 tablets – INR 22,500
- 120 tablets – INR 45,000
Note: price may be change as per manufacturer and the government guidelines.
Situation of Prostate Cancer and Role of Apalutamide
The prostate cancer is estimated to manifold by 1.7 million cases by 2030. This alarming calculation is based on the aging and growth of cancer globally.
In India itself, prostate cancer has reached the second most common threatening underlying cancer cause. Not only this but also, it is the sixth major reason for deaths by cancer among men.
As per BDR Pharmaceuticals, Apatide approved for –
- Non-Metastatic Castration resistant prostate cancer
- Metastatic Castration sensitive prostate cancer
- Apalutamide is here to be instrumental in improving overall survival (OS) and radiographic progression-free survival in patients.
- When administered along with anti-androgen therapy, Apalutamide will significantly improve chances for survival within Metastatic Castration Sensitive Prostate Cancer patients.
Final Words
The BDR Pharmaceuticals generic medication is capable of contributing to the overall quality of life when it comes to health-related issues. It works well along with its administration with androgen-deprivation therapy.
Being a major contributor in manufacturing of Indian Cancer medicines, BDR Pharmaceuticals is speaking of pan India affordability. It is looked upon as a “niche” entity in manufacturing of Pharmaceutical APIs and for new age formulations as well.
The company has earned eminence when it comes to manufacturing Indian Cancer medicines, concentrating on four specialized therapeutic segments – Oncology, Critical Care, Gynecology, and Neurology.
The company is a key player in the manufacturing of Indian Cancer medicines, has contributed to the treatment of Prostate Cancer starting with Abiraterone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.